Suberoylanilide hydroxamic acid (SAHA; vorinostat) causes bone loss by inhibiting immature osteoblasts

Bone

Volumn 48, Issue 5, 2011, Pages 1117-1126

  McGee Lawrence, Meghan E ^a   McCleary Wheeler, Angela L ^a   Secreto, Frank J ^a   Razidlo, David F ^a   Zhang, Minzhi ^a   Stensgard, Bridget A ^a   Li, Xiaodong ^a   Stein, Gary S ^b   Lian, Jane B ^b   Westendorf, Jennifer J ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

H2AX; Hdac; Histone deacetylase inhibitor; Osteoblasts; Zolinza

Indexed keywords

COLLAGEN TYPE 1; MESSENGER RNA; OSTEOCALCIN; OSTEOPONTIN; PROCOLLAGEN TYPE 1 AMINOTERMINAL PROPEPTIDE; REGULATOR PROTEIN; TRANSCRIPTION FACTOR OSTERIX; TRANSCRIPTION FACTOR RUNX2; UNCLASSIFIED DRUG; VORINOSTAT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE DENSITY; BONE MARROW CELL; BONE MASS; BONE MINERAL; BONE REMODELING; BONE TISSUE; C57BL 6 MOUSE; CELL ACTIVITY; CELL ADHESION; CELL COUNT; CELL CULTURE; CELL CYCLE ARREST; CELL DIFFERENTIATION; CELL MATURATION; CONTROLLED STUDY; CORTICAL BONE; DNA DAMAGE; DRUG MECHANISM; FEMUR; FEMUR SHAFT; GENE EXPRESSION; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OSSIFICATION; OSTEOBLAST; OSTEOLYSIS; PROTEIN BLOOD LEVEL; TIBIA; TRABECULAR BONE; TREATMENT DURATION;

ACETYLATION; ANIMALS; BIOLOGICAL MARKERS; BODY WEIGHT; BONE MARROW CELLS; BONE REMODELING; BONE RESORPTION; CELL COUNT; CELL CYCLE; CELL DIFFERENTIATION; COLONY-FORMING UNITS ASSAY; DNA DAMAGE; FEMUR; GENE EXPRESSION REGULATION; HISTONES; HYDROXAMIC ACIDS; MALE; MICE; MICE, INBRED C57BL; OSTEOBLASTS; OSTEOGENESIS; PEPTIDE FRAGMENTS; PROCOLLAGEN; TIME FACTORS;

EID: 79954548904     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2011.01.007     Document Type: Article

References (69)

1. Haberland M., Montgomery R.L., Olson E.N. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet 2009, 10:32-42.
2. Glozak M.A., Sengupta N., Zhang X., Seto E. Acetylation and deacetylation of non-histone proteins. Gene 2005, 363:15-23.
3. Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C., Olsen J.V., Mann M. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 2009, 325:834-840.
4. Zhou Q., Chaerkady R., Shaw P.G., Kensler T.W., Pandey A., Davidson N.E. Screening for therapeutic targets of vorinostat by SILAC-based proteomic analysis in human breast cancer cells. Proteomics 2010, 10:1029-1039.
5. Jeon E.J., Lee K.Y., Choi N.S., Lee M.H., Kim H.N., Jin Y.H., Ryoo H.M., Choi J.Y., Yoshida M., Nishino N., Oh B.C., Lee K.S., Lee Y.H., Bae S.C. Bone morphogenetic protein-2 stimulates Runx2 acetylation. J Biol Chem 2006, 281:16502-16511.
6. Juan L.J., Shia W.J., Chen M.H., Yang W.M., Seto E., Lin Y.S., Wu C.W. Histone deacetylases specifically down-regulate p53-dependent gene activation. J Biol Chem 2000, 275:20436-20443.
7. Luo J., Su F., Chen D., Shiloh A., Gu W. Deacetylation of p53 modulates its effect on cell growth and apoptosis. Nature 2000, 408:377-381.
8. Yuan Z.L., Guan Y.J., Chatterjee D., Chin Y.E. Stat3 dimerization regulated by reversible acetylation of a single lysine residue. Science 2005, 307:269-273.
9. Kumagai T., Wakimoto N., Yin D., Gery S., Kawamata N., Takai N., Komatsu N., Chumakov A., Imai Y., Koeffler H.P. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells. Int J Cancer 2007, 121:656-665.
10. Phiel C.J., Zhang F., Huang E.Y., Guenther M.G., Lazar M.A., Klein P.S. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 2001, 276:36734-36741.
11. Lin H.S., Hu C.Y., Chan H.Y., Liew Y.Y., Huang H.P., Lepescheux L., Bastianelli E., Baron R., Rawadi G., Clement-Lacroix P. Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents. Br J Pharmacol 2007, 150:862-872.
12. Tao R., de Zoeten E.F., Ozkaynak E., Chen C., Wang L., Porrett P.M., Li B., Turka L.A., Olson E.N., Greene M.I., Wells A.D., Hancock W.W. Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat Med 2007, 13:1299-1307.
13. Shein N.A., Grigoriadis N., Alexandrovich A.G., Simeonidou C., Lourbopoulos A., Polyzoidou E., Trembovler V., Mascagni P., Dinarello C.A., Shohami E. Histone deacetylase inhibitor ITF2357 is neuroprotective, improves functional recovery, and induces glial apoptosis following experimental traumatic brain injury. FASEB J 2009, 23:4266-4275.
14. Hutt D.M., Herman D., Rodrigues A.P., Noel S., Pilewski J.M., Matteson J., Hoch B., Kellner W., Kelly J.W., Schmidt A., Thomas P.J., Matsumura Y., Skach W.R., Gentzsch M., Riordan J.R., Sorscher E.J., Okiyoneda T., Yates J.R., Lukacs G.L., Frizzell R.A., Manning G., Gottesfeld J.M., Balch W.E. Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis. Nat Chem Biol 2010, 6:25-33.
15. McGee-Lawrence M.E., Westendorf J.J. Histone deacetylases in skeletal development and bone mass maintenance. Gene 2010.
16. Jensen E.D., Nair A.K., Westendorf J.J. Histone deacetylase co-repressor complex control of Runx2 and bone formation. Crit Rev Eukaryot Gene Expr 2007, 17:187-196.
17. Yi T., Baek J.H., Kim H.J., Choi M.H., Seo S.B., Ryoo H.M., Kim G.S., Woo K.M. Trichostatin A-mediated upregulation of p21(WAF1) contributes to osteoclast apoptosis. Exp Mol Med 2007, 39:213-221.
18. Schroeder T.M., Westendorf J.J. Histone deacetylase inhibitors promote osteoblast maturation. J Bone Miner Res 2005, 20:2254-2263.
19. Haberland M., Carrer M., Mokalled M.H., Montgomery R.L., Olson E.N. Redundant control of adipogenesis by histone deacetylases 1 and 2. J Biol Chem 2010, 285:14663-14670.
20. Lee S., Park J.R., Seo M.S., Roh K.H., Park S.B., Hwang J.W., Sun B., Seo K., Lee Y.S., Kang S.K., Jung J.W., Kang K.S. Histone deacetylase inhibitors decrease proliferation potential and multilineage differentiation capability of human mesenchymal stem cells. Cell Prolif 2009, 42:711-720.
21. Cho H.H., Park H.T., Kim Y.J., Bae Y.C., Suh K.T., Jung J.S. Induction of osteogenic differentiation of human mesenchymal stem cells by histone deacetylase inhibitors. J Cell Biochem 2005, 96:533-542.
22. Schroeder T.M., Kahler R.A., Li X., Westendorf J.J. Histone deacetylase 3 interacts with runx2 to repress the osteocalcin promoter and regulate osteoblast differentiation. J Biol Chem 2004, 279:41998-42007.
23. Westendorf J.J., Zaidi S.K., Cascino J.E., Kahler R., van Wijnen A.J., Lian J.B., Yoshida M., Stein G.S., Li X. Runx2 (Cbfa1, AML-3) interacts with histone deacetylase 6 and represses the p21(CIP1/WAF1) promoter. Mol Cell Biol 2002, 22:7982-7992.
24. Jensen E.D., Schroeder T.M., Bailey J., Gopalakrishnan R., Westendorf J.J. Histone deacetylase 7 associates with Runx2 and represses its activity during osteoblast maturation in a deacetylation-independent manner. J Bone Miner Res 2008, 23:361-372.
25. Lee H.W., Suh J.H., Kim A.Y., Lee Y.S., Park S.Y., Kim J.B. Histone deacetylase 1-mediated histone modification regulates osteoblast differentiation. Mol Endocrinol 2006, 20:2432-2443.
26. Kang J.S., Alliston T., Delston R., Derynck R. Repression of Runx2 function by TGF-beta through recruitment of class II histone deacetylases by Smad3. EMBO J 2005, 24:2543-2555.
27. Vega R.B., Matsuda K., Oh J., Barbosa A.C., Yang X., Meadows E., McAnally J., Pomajzl C., Shelton J.M., Richardson J.A., Karsenty G., Olson E.N. Histone deacetylase 4 controls chondrocyte hypertrophy during skeletogenesis. Cell 2004, 119:555-566.
28. Zhang Y., Kwon S., Yamaguchi T., Cubizolles F., Rousseaux S., Kneissel M., Cao C., Li N., Cheng H.L., Chua K., Lombard D., Mizeracki A., Matthias G., Alt F.W., Khochbin S., Matthias P. Mice lacking histone deacetylase 6 have hyperacetylated tubulin but are viable and develop normally. Mol Cell Biol 2008, 28:1688-1701.
29. Rivadeneira F., Styrkarsdottir U., Estrada K., Halldorsson B.V., Hsu Y.H., Richards J.B., Zillikens M.C., Kavvoura F.K., Amin N., Aulchenko Y.S., Cupples L.A., Deloukas P., Demissie S., Grundberg E., Hofman A., Kong A., Karasik D., van Meurs J.B., Oostra B., Pastinen T., Pols H.A., Sigurdsson G., Soranzo N., Thorleifsson G., Thorsteinsdottir U., Williams F.M., Wilson S.G., Zhou Y., Ralston S.H., van Duijn C.M., Spector T., Kiel D.P., Stefansson K., Ioannidis J.P., Uitterlinden A.G. Twenty bone-mineral-density loci identified by large-scale meta-analysis of genome-wide association studies. Nat Genet 2009, 41:1199-1206.
30. Li H., Xie H., Liu W., Hu R., Huang B., Tan Y.F., Xu K., Sheng Z.F., Zhou H.D., Wu X.P., Luo X.H. A novel microRNA targeting HDAC5 regulates osteoblast differentiation in mice and contributes to primary osteoporosis in humans. J Clin Invest 2009, 119:3666-3677.
31. Haberland M., Mokalled M.H., Montgomery R.L., Olson E.N. Epigenetic control of skull morphogenesis by histone deacetylase 8. Genes Dev 2009, 23:1625-1630.
32. Razidlo D.F., Whitney T.J., Casper M.E., McGee-Lawrence M.E., Stensgard B.A., Li X., Secreto F.J., Knutson S.K., Hiebert S.W., Westendorf J.J. Histone deacetylase 3 depletion in osteo/chondroprogenitor cells decreases bone density and increases marrow fat. PLoS ONE 2010, 5:e11492.
33. Subha K., Kumar G.R. Assessment for the identification of better HDAC inhibitor class through binding energy calculations and descriptor analysis. Bioinformation 2008, 3:218-222.
34. Fischle W., Dequiedt F., Hendzel M.J., Guenther M.G., Lazar M.A., Voelter W., Verdin E. Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR. Mol Cell 2002, 9:45-57.
35. Guo C.Y., Ronen G.M., Atkinson S.A. Long-term valproate and lamotrigine treatment may be a marker for reduced growth and bone mass in children with epilepsy. Epilepsia 2001, 42:1141-1147.
36. Sato Y., Kondo I., Ishida S., Motooka H., Takayama K., Tomita Y., Maeda H., Satoh K. Decreased bone mass and increased bone turnover with valproate therapy in adults with epilepsy. Neurology 2001, 57:445-449.
37. Vestergaard P., Rejnmark L., Mosekilde L. Fracture risk associated with use of antiepileptic drugs. Epilepsia 2004, 45:1330-1337.
38. Vajda F.J., O'Brien T.J., Hitchcock A., Graham J., Cook M., Lander C., Eadie M.J. Critical relationship between sodium valproate dose and human teratogenicity: results of the Australian register of anti-epileptic drugs in pregnancy. J Clin Neurosci 2004, 11:854-858.
39. Senn S.M., Kantor S., Poulton I.J., Morris M.J., Sims N.A., O'Brien T.J., Wark J.D. Adverse effects of valproate on bone: defining a model to investigate the pathophysiology. Epilepsia 2010.
40. Kim S.H., Lee J.W., Choi K.G., Chung H.W., Lee H.W. A 6-month longitudinal study of bone mineral density with antiepileptic drug monotherapy. Epilepsy Behav 2007, 10:291-295.
41. Tsukahara H., Kimura K., Todoroki Y., Ohshima Y., Hiraoka M., Shigematsu Y., Tsukahara Y., Miura M., Mayumi M. Bone mineral status in ambulatory pediatric patients on long-term anti-epileptic drug therapy. Pediatr Int 2002, 44:247-253.
42. Rieger-Wettengl G., Tutlewski B., Stabrey A., Rauch F., Herkenrath P., Schauseil-Zipf U., Schoenau E. Analysis of the musculoskeletal system in children and adolescents receiving anticonvulsant monotherapy with valproic acid or carbamazepine. Pediatrics 2001, 108:E107.
43. Loscher W. Valproate induced changes in GABA metabolism at the subcellular level. Biochem Pharmacol 1981, 30:1364-1366.
44. van der Laan J.W., de Boer T., Bruinvels J. Di-n-propylacetate and GABA degradation. Preferential inhibition of succinic semialdehyde dehydrogenase and indirect inhibition of GABA-transaminase. J Neurochem 1979, 32:1769-1780.
45. Mann B.S., Johnson J.R., Cohen M.H., Justice R., Pazdur R. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 2007, 12:1247-1252.
46. Pratap J., Akech J., Wixted J.J., Szabo G., Hussain S., McGee-Lawrence M.E., Li X., Bedard K., Dhillon R.J., van Wijnen A.J., Stein J.L., Stein G.S., Westendorf J.J., Lian J.B. The histone deacetylase inhibitor, vorinostat, reduces tumor growth at the metastatic bone site and associated osteolysis, but promotes normal bone loss. Mol Cancer Ther 2010, 9:3210-3220.
47. Butler L.M., Agus D.B., Scher H.I., Higgins B., Rose A., Cordon-Cardo C., Thaler H.T., Rifkind R.A., Marks P.A., Richon V.M. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res 2000, 60:5165-5170.
48. Campbell R.A., Sanchez E., Steinberg J., Shalitin D., Li Z.W., Chen H., Berenson J.R. Vorinostat enhances the antimyeloma effects of melphalan and bortezomib. Eur J Haematol 2010, 84:201-211.
49. Bouxsein M.L., Boyd S.K., Christiansen B.A., Guldberg R.E., Jepsen K.J., Muller R. Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. J Bone Miner Res 2010, 25:1468-1486.
50. Parfitt A.M., Drezner M.K., Glorieux F.H., Kanis J.A., Malluche H., Meunier P.J., Ott S.M., Recker R.R. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 1987, 2:595-610.
51. Pfaffl M.W. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001, 29:e45.
52. Bradley D., Rathkopf D., Dunn R., Stadler W.M., Liu G., Smith D.C., Pili R., Zwiebel J., Scher H., Hussain M. Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): trial results and interleukin-6 analysis: a study by the Department of Defense Prostate Cancer Clinical Trial Consortium and University of Chicago Phase 2 Consortium. Cancer 2009, 115:5541-5549.
53. Kerr J.S., Galloway S., Lagrutta A., Armstrong M., Miller T., Richon V.M., Andrews P.A. Nonclinical safety assessment of the histone deacetylase inhibitor vorinostat. Int J Toxicol 2010, 29:3-19.
54. Kelly W.K., O'Connor O.A., Krug L.M., Chiao J.H., Heaney M., Curley T., MacGregore-Cortelli B., Tong W., Secrist J.P., Schwartz L., Richardson S., Chu E., Olgac S., Marks P.A., Scher H., Richon V.M. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 2005, 23:3923-3931.
55. Duvic M., Talpur R., Ni X., Zhang C., Hazarika P., Kelly C., Chiao J.H., Reilly J.F., Ricker J.L., Richon V.M., Frankel S.R. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 2007, 109:31-39.
56. Olsen E.A., Kim Y.H., Kuzel T.M., Pacheco T.R., Foss F.M., Parker S., Frankel S.R., Chen C., Ricker J.L., Arduino J.M., Duvic M. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 2007, 25:3109-3115.
57. de Boer J., Licht R., Bongers M., van der Klundert T., Arends R., van Blitterswijk C. Inhibition of histone acetylation as a tool in bone tissue engineering. Tissue Eng 2006, 12:2927-2937.
58. Di Bernardo G., Squillaro T., Dell'Aversana C., Miceli M., Cipollaro M., Cascino A., Altucci L., Galderisi U. Histone deacetylase inhibitors promote apoptosis and senescence in human mesenchymal stem cells. Stem Cells Dev 2009, 18:573-581.
59. Di Bernardo G., Alessio N., Dell'Aversana C., Casale F., Teti D., Cipollaro M., Altucci L., Galderisi U. Impact of histone deacetylase inhibitors SAHA and MS-275 on DNA repair pathways in human mesenchymal stem cells. J Cell Physiol 2010, 225:537-544.
60. Hossain A., Jung L.K. Expression of bone specific alkaline phosphatase on human B cells. Cell Immunol 2008, 253:66-70.
61. Iwami K., Moriyama T. Effects of short chain fatty acid, sodium butyrate, on osteoblastic cells and osteoclastic cells. Int J Biochem 1993, 25:1631-1635.
62. Kumandas S., Koklu E., Gumus H., Koklu S., Kurtoglu S., Karakukcu M., Keskin M. Effect of carbamezapine and valproic acid on bone mineral density, IGF-I and IGFBP-3. J Pediatr Endocrinol Metab 2006, 19:529-534.
63. Babayigit A., Dirik E., Bober E., Cakmakci H. Adverse effects of antiepileptic drugs on bone mineral density. Pediatr Neurol 2006, 35:177-181.
64. Oner N., Kaya M., Karasalihoglu S., Karaca H., Celtik C., Tutunculer F. Bone mineral metabolism changes in epileptic children receiving valproic acid. J Paediatr Child Health 2004, 40:470-473.
65. Boluk A., Guzelipek M., Savli H., Temel I., Ozisik H.I., Kaygusuz A. The effect of valproate on bone mineral density in adult epileptic patients. Pharmacol Res 2004, 50:93-97.
66. Nissen-Meyer L.S., Svalheim S., Tauboll E., Reppe S., Lekva T., Solberg L.B., Melhus G., Reinholt F.P., Gjerstad L., Jemtland R. Levetiracetam, phenytoin, and valproate act differently on rat bone mass, structure, and metabolism. Epilepsia 2007, 48:1850-1860.
67. Sheth R.D., Wesolowski C.A., Jacob J.C., Penney S., Hobbs G.R., Riggs J.E., Bodensteiner J.B. Effect of carbamazepine and valproate on bone mineral density. J Pediatr 1995, 127:256-262.
68. Elliott J.O., Jacobson M.P., Haneef Z. Homocysteine and bone loss in epilepsy. Seizure 2007, 16:22-34.
69. Mezuk B., Morden N.E., Ganoczy D., Post E.P., Kilbourne A.M. Anticonvulsant use, bipolar disorder, and risk of fracture among older adults in the veterans health administration. Am J Geriatr Psychiatry 2010, 18:245-255.